Tanvex BioPharma Inc banner

Tanvex BioPharma Inc
TWSE:6541

Watchlist Manager
Tanvex BioPharma Inc Logo
Tanvex BioPharma Inc
TWSE:6541
Watchlist
Price: 44 TWD 2.8% Market Closed
Market Cap: NT$11.7B

Cash Flow Statement

Cash Flow Statement
Tanvex BioPharma Inc

Rotate your device to view
Cash Flow Statement
Currency: TWD
Dec-2016 Mar-2017 Jun-2017 Sep-2017 Dec-2017 Mar-2018 Jun-2018 Sep-2018 Dec-2018 Mar-2019 Jun-2019 Sep-2019 Dec-2019 Mar-2020 Jun-2020 Sep-2020 Dec-2020 Mar-2021 Jun-2021 Sep-2021 Dec-2021 Mar-2022 Jun-2022 Sep-2022 Dec-2022 Mar-2023 Jun-2023 Sep-2023 Dec-2023 Mar-2024 Jun-2024 Sep-2024 Dec-2024 Mar-2025 Jun-2025 Sep-2025
Operating Cash Flow
Net Income
(1 244)
(1 432)
(1 462)
(1 469)
(1 410)
(1 389)
(1 681)
(1 850)
(1 894)
(2 081)
(1 974)
(2 187)
(2 274)
(2 374)
(2 403)
(2 170)
(2 104)
(1 903)
(1 720)
(1 663)
(1 543)
(1 460)
(1 508)
(1 514)
(1 641)
(1 917)
(1 996)
(2 097)
(2 137)
(1 947)
(1 808)
(1 621)
(1 381)
(1 432)
(1 406)
(1 361)
Depreciation & Amortization
118
123
127
131
133
134
137
140
143
162
180
198
216
216
215
214
220
227
232
239
244
249
260
277
282
293
307
311
325
320
310
300
289
314
337
352
Stock-Based Compensation
136
162
186
185
172
174
186
177
164
159
150
163
156
145
93
51
80
31
45
51
53
47
55
63
68
284
342
351
327
0
0
0
0
0
0
2
Other Non-Cash Items
130
148
167
162
186
186
194
178
115
101
86
99
109
108
68
68
81
77
13
(1)
6
2
103
116
120
333
384
383
367
133
59
47
39
115
90
48
Cash Taxes Paid
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
1
1
1
1
1
1
Cash Interest Paid
0
0
0
0
0
0
0
0
0
4
8
12
16
15
14
13
18
25
32
41
46
48
51
54
55
55
55
55
57
58
58
58
53
52
50
48
Change in Working Capital
164
84
47
40
(121)
(97)
82
(3)
30
63
(119)
(20)
51
66
133
54
16
(38)
23
(2)
(94)
(65)
(238)
(224)
(94)
(61)
(44)
91
11
79
78
(9)
(98)
(142)
(156)
(163)
Cash from Operating Activities
(833)
N/A
(1 078)
-29%
(1 121)
-4%
(1 137)
-1%
(1 212)
-7%
(1 166)
+4%
(1 269)
-9%
(1 535)
-21%
(1 606)
-5%
(1 756)
-9%
(1 827)
-4%
(1 911)
-5%
(1 899)
+1%
(1 984)
-5%
(1 986)
0%
(1 835)
+8%
(1 788)
+3%
(1 636)
+8%
(1 452)
+11%
(1 427)
+2%
(1 387)
+3%
(1 273)
+8%
(1 384)
-9%
(1 345)
+3%
(1 334)
+1%
(1 352)
-1%
(1 350)
+0%
(1 311)
+3%
(1 434)
-9%
(1 414)
+1%
(1 361)
+4%
(1 283)
+6%
(1 151)
+10%
(1 146)
+0%
(1 135)
+1%
(1 123)
+1%
Investing Cash Flow
Capital Expenditures
(249)
(240)
(183)
(175)
(117)
(114)
(122)
(97)
(109)
(101)
(97)
(96)
(94)
(70)
(73)
(75)
(67)
(73)
(55)
(45)
(30)
(31)
(45)
(63)
(96)
(93)
(85)
(88)
(71)
(101)
(122)
(99)
(111)
(83)
(121)
(236)
Other Items
(1 615)
(1 606)
(1 617)
(975)
456
165
161
(467)
(804)
(510)
119
500
1 913
1 907
1 292
741
(176)
(185)
(182)
10
6
19
(201)
(5)
(1)
0
217
(10)
(12)
(12)
(143)
3
2
1 010
1 067
846
Cash from Investing Activities
(1 863)
N/A
(1 845)
+1%
(1 799)
+2%
(1 150)
+36%
340
N/A
51
-85%
39
-23%
(564)
N/A
(912)
-62%
(611)
+33%
23
N/A
404
+1 684%
1 819
+350%
1 837
+1%
1 218
-34%
666
-45%
(243)
N/A
(258)
-6%
(237)
+8%
(34)
+86%
(25)
+28%
(12)
+52%
(246)
-1 967%
(68)
+72%
(97)
-44%
(92)
+5%
133
N/A
(99)
N/A
(84)
+15%
(113)
-35%
(265)
-135%
(96)
+64%
(109)
-14%
928
N/A
946
+2%
610
-36%
Financing Cash Flow
Net Issuance of Common Stock
3 342
14
12
16
1 664
1 664
1 664
3 793
2 146
2 160
2 158
26
982
966
969
972
1 703
1 706
1 709
3 381
1 690
1 688
1 681
6
7
7
1 202
1 206
1 207
1 209
1 449
1 444
1 440
1 450
17
1 263
Net Issuance of Debt
0
0
0
0
0
0
0
0
0
(16)
(33)
(50)
(68)
(70)
23
23
27
21
(80)
(85)
(93)
(102)
(112)
(124)
(131)
(130)
(122)
(117)
(128)
237
(153)
(161)
(185)
(544)
(172)
(177)
Cash Paid for Dividends
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
(2)
0
0
Other
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
(2)
(2)
0
Cash from Financing Activities
3 342
N/A
14
-100%
12
-18%
16
+36%
1 664
+10 566%
1 664
+0%
1 664
N/A
3 793
+128%
2 146
-43%
2 144
0%
2 126
-1%
(25)
N/A
914
N/A
895
-2%
993
+11%
995
+0%
1 730
+74%
1 728
0%
1 630
-6%
3 296
+102%
1 597
-52%
1 586
-1%
1 569
-1%
(118)
N/A
(123)
-5%
(123)
+0%
1 080
N/A
1 090
+1%
1 080
-1%
1 445
+34%
1 296
-10%
1 281
-1%
1 255
-2%
905
-28%
(157)
N/A
1 087
N/A
Change in Cash
Effect of Foreign Exchange Rates
(102)
(44)
(27)
17
(83)
(66)
(75)
(51)
(7)
37
9
35
(38)
(35)
(75)
(91)
(58)
(52)
(49)
(36)
(31)
(43)
64
130
118
101
51
22
32
40
21
(35)
1
5
5
77
Net Change in Cash
543
N/A
(2 954)
N/A
(2 936)
+1%
(2 254)
+23%
708
N/A
483
-32%
360
-26%
1 642
+356%
(379)
N/A
(185)
+51%
331
N/A
(1 496)
N/A
797
N/A
714
-10%
150
-79%
(264)
N/A
(359)
-36%
(218)
+39%
(109)
+50%
1 799
N/A
154
-91%
258
+67%
3
-99%
(1 400)
N/A
(1 437)
-3%
(1 467)
-2%
(85)
+94%
(297)
-249%
(405)
-36%
(42)
+90%
(309)
-644%
(133)
+57%
(4)
+97%
692
N/A
(340)
N/A
652
N/A
Free Cash Flow
Free Cash Flow
(1 082)
N/A
(1 318)
-22%
(1 303)
+1%
(1 312)
-1%
(1 329)
-1%
(1 280)
+4%
(1 390)
-9%
(1 632)
-17%
(1 715)
-5%
(1 857)
-8%
(1 923)
-4%
(2 007)
-4%
(1 992)
+1%
(2 055)
-3%
(2 060)
0%
(1 910)
+7%
(1 855)
+3%
(1 709)
+8%
(1 507)
+12%
(1 472)
+2%
(1 417)
+4%
(1 304)
+8%
(1 429)
-10%
(1 408)
+1%
(1 430)
-2%
(1 445)
-1%
(1 434)
+1%
(1 399)
+2%
(1 505)
-8%
(1 515)
-1%
(1 483)
+2%
(1 382)
+7%
(1 261)
+9%
(1 229)
+3%
(1 256)
-2%
(1 360)
-8%
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett